Patheon Inc. (TSX: PTI) today announced that Patheon has entered into a five-year master supply agreement with Merck & Co., Inc. (NYSE: MRK) to provide commercial manufacturing and pharmaceutical development services to Merck, and that Merck has selected Patheon as one of Merck’s strategic partners for commercial manufacturing and pharmaceutical development services.
